Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LTP 001

Next Previous
Drug Profile

LTP 001

Alternative Names: LTP-001

Latest Information Update: 19 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Antifibrotics
  • Mechanism of Action SMURF1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension

Most Recent Events

  • 06 Mar 2026 Novartis plans a phase I trial for Healthy volunteers in Netherlands (PO) (CTIS2025-524172-29-00) (CLTP001A12101)
  • 31 Dec 2025 Novartis plans regulatory filings of LTP 001 for Pulmonary arterial hypertension on or after 2029 (Novartis pipeline, December 2025)
  • 24 Oct 2024 Novartis Pharmaceuticals initiates a phase I/II trial for Pulmonary arterial hypertension in the US (PO) (NCT06649110)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top